BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)March 25, 2026
Share Facebook Twitter LinkedIn Pinterest Email Notable healthcare headlines for the week: Viatris, Novavax and UnitedHealth in focus
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)March 25, 2026
Absci outlines $25B annual market potential for ABS-201 in AGA and advances endometriosis clinical program (NASDAQ:ABSI)March 25, 2026
By Press Room
By Press Room
By Press Room
